Literature DB >> 7842274

Neurologic consequences of hypertension and antihypertensive drug therapy.

J M Wyss1, T van Groen.   

Abstract

Untreated essential hypertension leads to cardiovascular and renal disease and stroke, but antihypertensive drug therapy effectively reduces these consequences of hypertension. Several studies indicate that hypertension can negatively impact on cognitive function, especially on learning and memory, but the ability of antihypertensive drugs to ameliorate these cognitive dysfunctions is less clear. None of the recent studies convincingly demonstrates that any of the antihypertensive drugs currently in use has a major deleterious effect on cognition in hypertensive patients, but some of the drugs more reliably benefit cognitive function in the hypertensive patient. As a class, the angiotensin-converting enzyme inhibitors most consistently lead to cognitive improvement in the overall hypertensive population, but beta 1-adrenergic receptor blockers and a subset of calcium channel blockers appear to have very similar effects. Animal studies and clinical studies in demented patients suggest that angiotensin-converting enzyme in the cerebral cortex plays a role in normal learning and memory, a finding that provides a theoretic foundation to the beneficial actions of this class of drugs on cognitive function in hypertensive individuals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7842274     DOI: 10.1097/00041552-199403000-00015

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  2 in total

1.  Chronic, severe hypertension does not impair spatial learning and memory in Sprague-Dawley rats.

Authors:  I Kadish; T van Groen; J M Wyss
Journal:  Learn Mem       Date:  2001 Mar-Apr       Impact factor: 2.460

Review 2.  Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention.

Authors:  Miia Kivipelto; Mikko P Laakso; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.